How Long Does Semaglutide Take to Get in Your System — and When Does It Start Working?

The misconception worth correcting first: 'active in your system' is not the same as 'working'

The most common confusion around semaglutide's timeline is treating 'detectable in the blood' and 'producing results on the scales' as the same thing. They're not, and conflating them leads to a lot of unnecessary anxiety in the first few weeks of treatment.

Semaglutide is detectable in the bloodstream within hours of a subcutaneous injection. Its half-life is roughly one week, which is precisely why weekly dosing works: by the time your next injection is due, you still have meaningful levels circulating. But 'in your system' is not the same as 'at therapeutic steady state'. That takes around four to five weeks of consecutive weekly doses. Until then, levels are still climbing toward their stable plateau, and the effect on appetite and food intake is building in parallel.

Think of it like filling a bath with a slow tap. Water's in the tub from the moment you turn it on, but it takes time to reach the depth you actually bathe in. If you're waiting for Wegovy to produce noticeable weight loss, measuring progress in the first two or three weeks is likely to feel deflating, and it isn't representative of what the medicine will do over a full course of treatment.

The NHS medicines information for semaglutide confirms this gradual onset: the medicine works by activating GLP-1 receptors, slowing how quickly the stomach empties and signalling to the brain that you've eaten enough. None of those mechanisms switch on like a light.

What the first few weeks of semaglutide actually feel like, and what to notice

Most people starting on Wegovy begin at 0.25 mg weekly. At that level, don't expect dramatic appetite suppression. The starting dose is there to let your body adjust, the GI side effects (nausea, loose stools, belching, that general unsettled feeling after eating) are most likely at the beginning and after each dose increase, and the lower starting dose reduces their intensity. Your prescriber sets the schedule; your job is to stay consistent.

Between weeks two and four, many people begin to notice something shifting, portions feel like enough, the pull toward snacking softens, fullness arrives sooner. This is semaglutide becoming active in a meaningful sense, even if weight hasn't moved much yet. It's worth paying attention to these early appetite signals, because they're a practical signal that the medicine is doing what it should. A quick check you can do: notice whether you're leaving food on the plate at a meal that would previously have been finished easily. That small shift, if it starts appearing around week three or four, is a reliable early marker.

Understanding how long Wegovy stays in your system between doses also helps explain why consistency matters, missing a dose creates a dip in the steady state that can briefly disrupt appetite control. If you do miss one, your prescriber and the Patient Information Leaflet should guide next steps; don't adjust timing yourself.

Weight loss, when it comes, tends to accelerate as the dose increases over the titration schedule toward the 2.4 mg maintenance level. The early-weeks Wegovy results picture is useful context here, clinical trial outcomes reflect the full multi-month schedule, not just the first pen.

The science behind semaglutide's pharmacokinetics, why it behaves differently from other medicines you might have taken

Semaglutide's pharmacokinetic profile is unusual among weight-management medicines, and understanding it removes most of the timeline confusion. After a subcutaneous injection, it binds tightly to albumin (a protein in the blood), which slows its breakdown and extends its half-life to approximately one week. That binding is what makes once-weekly dosing viable; most other injectable medicines need to be given daily or more.

Because of this long half-life, semaglutide accumulates with each successive weekly dose during the first month of treatment. The drug's concentration effectively doubles, then settles, over the first four to five injections. This is also why semaglutide persists in the body for several weeks after the last dose, clinically relevant if you need surgery or are planning to conceive, in which case timing needs to be discussed with your prescriber well in advance.

The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, a figure that reflects the full accumulation period, the titration schedule, and sustained treatment. It doesn't describe what week four looks like. That context matters when people measure themselves early and feel discouraged.

For the oral version, Wegovy tablets (approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management), absorption is taken up via a different mechanism. The tablet is taken first thing in the morning on an empty stomach; bioavailability is lower than the injection, and the titration to the 25 mg maintenance tablet takes longer, but the underlying pharmacology (GLP-1 receptor activation, appetite regulation, gradual accumulation) is the same.

The NHS medicines page for semaglutide covers the clinical detail on how the medicine works, and is worth bookmarking alongside the Patient Information Leaflet that comes with your pen. If you're considering treatment, our overview of Wegovy sets out what the private prescription route involves, and you can check what Wegovy costs privately as part of planning. When you're ready, checking your eligibility with our prescribers is a straightforward first step.